Although not all of these side effects may occur, if they do occur they may need medical attention. -This drug penetrates extensively into various tissues and bodily fluids, including sinus mucosa, prostatic tissue, bone, the central nervous system, bronchial secretions, and middle ear exudates.
Contact the applicable plan Since azithromycin concentrates preferentially in brain tissue and not in cerebral spinal fluid, it should not be used to treat meningitis. Indicated for treatment of community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy500 mg PO x 1 dose on Day 1, followed by 250 mg PO qDay on Days 2-5 Indicated for treatment of pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative therapy in individuals who cannot use first-line therapy500 mg PO x 1 dose on Day 1, followed by 250 mg PO qDay on Days 2-5 Indicated for treatment of uncomplicated skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae500 mg PO x 1 dose on Day 1, followed by 250 mg PO qDay on Days 2-5 Indicated for treatment of acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniaeAlternatively, 500 mg PO x 1 dose on Day 1, followed by 250 mg PO qDay on Days 2-5Indicated for treatment of acute bacterial sinusitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniaeIndicated for treatment of genital ulcer disease in men due to Haemophilus ducreyi (chancroid)Efficacy in treatment of chancroid in women has not been establishedIndicated for treatment of urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeaeIndicated for treatment of pelvic inflammatory disease due to Chlamydia trachomatis, Neisseria gonorrhoeae, or Mycoplasma hominis in patients who require initial IV therapyIf anaerobic microorganisms are suspected of contributing to the infection, administer an antimicrobial agent with anaerobic activity in combination with azithromycinNote: Limited data available; no drug is FDA approved to treat COVID-19Azithromycin may be considered for use as part of an investigational protocol for patients with COVID-19 >45.5 kg: 500 mg PO once, then 250 mg once daily for 4 daysCurrent American Heart Association (AHA) guidelines recommend only for high-risk patientsUse only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycinIndicated for treatment of acute otitis media in patient >6 months of age caused by Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae≥6 months: 10 mg/kg PO x 1 dose on Day 1, followed by 5 mg/kg PO on Days 2-5 Indicated for treatment of pharyngitis/tonsillitis in patients >2 years of age caused by Streptococcus pyogenes as an alternative therapy in individuals who cannot use first-line therapy≥2 years: 12 mg/kg PO qDay for 5 days; not to exceed 500 mg/day Children and adolescents ≥45 kg: 1 g PO as single dose≤45 kg: 10 mg/kg (not to exceed 500 mg/dose) PO as single dose; then 5 mg/kg (not to exceed 250 mg/dose) PO qDay on days 2 through 5>45 kg: 500 mg PO once, then 250 mg once daily for 4 daysUse only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycinAllergic: Arthralgia, edema, urticaria and angioedemaCardiovascular: Arrhythmias (eg, ventricular tachycardia), hypotension, QT prolongation, and torsades de pointesGastrointestinal: Anorexia, constipation, dyspepsia, flatulence, vomiting/diarrhea, pseudomembranous colitis, pancreatitis, oral candidiasis, pyloric stenosis, and reports of tongue discolorationGeneral: Asthenia, paresthesia, fatigue, malaise and anaphylaxis (including fatalities). Discontinuation of the drug quickly reverses any unwanted myelosuppression.We conducted a prospective, randomized trial to assess whether hydroxyurea, given to keep the platelet count below 600,000 per cubic millimeter, reduces the incidence of thrombosis in patients with essential thrombocythemia who are at high risk for thrombotic complications.In a cohort of 198 patients seen at our two institutions who were given a diagnosis of essential thrombocythemia according to previously reported criteria,Base-line bleeding-time and coagulation studies, including measurement of the activated partial-thromboplastin time, one-stage prothrombin time, thrombin time, and fibrinogen levels, were performed according to standard methods. Detailed Hydroxyurea dosage information for adults and children. The median follow-up was 27 months. Available for Android and iOS devices. Find patient medical information for Hydroxyurea (Sickle Cell) Oral on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings. Prepare to become a physician, build your knowledge, lead a health care organization, and advance your career with NEJM Group information and services.Abnormalities in the number and function of platelets may contribute to thromboembolic complications in patients with essential thrombocythemia.